08.07.2016 • NewsChemoursDede Willamsdrinking water

DuPont Loses Another PFOA Case

(c) Angel Herrero de Frutos
(c) Angel Herrero de Frutos

DuPont has lost another round in a string of pending or completed class action lawsuits involving discharges of perfluorooctanoic acid (PFOA or C8) from the US chemical giant’s Washington Works in Parkersburg, West Virginia, now owned by spin-off Chemours. The since phased-out chemical used to make the company’s Teflon brand non-stick fluoropolymer coating eventually found its way into drinking water reserves in the states of West Virginia and Ohio.

In the latest judgment, after less than a full day of deliberation, a jury in Columbus, Ohio, found DuPont responsible for negligence and ordered the company to pay $5.1 million in associated damages to a West Virginia man. In addition, the jury found actual malice, signaling that the company will also face punitive damages.

A trial to determine the amount of the damages was scheduled to begin on Jul. 7. Chemours had previously agreed to cover damages awarded in the trials, but a company spokesperson recently told US media that, as DuPont is the only named defendant in the lawsuits, the spin-off might disclaim responsibility.

The first C 8 test trial ended in October 2015 with an award of $1.6 million to an Ohio woman, Carla Marie Bartlett, who had kidney cancer. A second case was settled on undisclosed terms.

In the case just tried, David Freeman, who has lived near the Washington Works plant since 1993 and blames DuPont for his testicular cancer, claimed the company knowingly dumped the chemical into local waterways. “Their goal was to protect the Teflon brand at the expense of the community,” Freeman’s lawyer told the jury.

Altogether, the US group faces 3,500 suits from people who claim they or their family members suffered health problems from drinking water contaminated with C8 produced in the DuPont plant. In 2005, the company paid $16.5 million to the US Environmental Protection Agency (EPA) to settle allegations it hid information on health risks associated with C8, including studies that showed birth defects in children of its employees who drank from the same water supply.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.